Summary & Overview
HCPCS Q5098: Ustekinumab-srlf (imuldosa) Biosimilar Injection, 1 mg
HCPCS Level II code Q5098 designates the biosimilar product ustekinumab-srlf (imuldosa) for injection, billed per 1 mg. This code enables standardized reporting and billing for a biosimilar monoclonal antibody therapy used in immunologic and inflammatory conditions where ustekinumab is indicated. Nationally, adoption of biosimilar billing codes like Q5098 affects payer formularies, contracting, and reimbursement pathways for high-cost biologic treatments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, commonly observed payer coverage patterns, and benchmarking elements relevant to billing and reimbursement. The publication also outlines typical places of service and what to expect when submitting claims for a biosimilar product billed per milligram.
This resource is intended to inform billing managers, revenue cycle staff, and policy analysts about the role of HCPCS Level II code Q5098 in claims processing, payer interactions, and clinical documentation workflows. Data not available in the input.
Billing Code Overview
HCPCS Level II code Q5098 represents the drug product ustekinumab-srlf (imuldosa), biosimilar, billed per 1 mg for injection. The service type is injectable biologic medication administration intended for subcutaneous or intravenous use depending on clinical protocol for the referenced biologic formulation. The typical site of service for this medication is outpatient infusion centers, hospital outpatient departments, ambulatory clinics, and physician offices where biologic injections or infusions are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with moderate-to-severe plaque psoriasis or active Crohn disease who requires subcutaneous biologic therapy with ustekinumab biosimilar Q5098 (imuldosa). The patient presents to an infusion suite, ambulatory infusion center, specialty clinic, or physician office for administration of a prefilled syringe or vial-converted dose. Prior to injection, the clinician verifies the patient’s identity, reviews current medications and recent laboratory monitoring (for example, tuberculosis screening and baseline complete blood count), confirms dosing based on weight and indication, documents informed consent and prior authorization coverage, and inspects the drug carton for product, lot, and expiration. The healthcare professional prepares the syringe in a clean area, administers the subcutaneous injection into the abdomen, thigh, or upper arm, observes the patient for immediate adverse reaction per facility protocol (typically 15–30 minutes), documents lot number and injection site, and schedules follow-up dosing and monitoring. Typical sites of service include outpatient physician offices (dermatology, gastroenterology), ambulatory infusion centers, and specialty pharmacy administered injection clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified service | When no modifier applies to the administration claim for . |